Adiponectin peptidomimetics for treating ocular disorders

Inventors

Hsu, Henry

Assignees

Allysta Pharmaceuticals Inc

Abstract

Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.

Core Innovation

The invention relates to compositions and methods for treating dry eye and ocular diseases associated with inflammation using an adiponectin peptidomimetic compound in a pharmaceutically acceptable carrier. The adiponectin peptidomimetic compound is selected from specific peptidomimetic sequences and derivatives identified by SEQ ID NOs, including D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser (SEQ ID NO:3), D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-β-Ala (SEQ ID NO:4), D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-β-AlaNH2 (SEQ ID NO:5), D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH2 (SEQ ID NO:6), and (D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-His-Pro)2-Dab-NH2 (SEQ ID NO:7). The therapeutic approach administers a therapeutically effective amount of the composition to a subject in need thereof for dry eye treatment.

The invention further addresses alleviating at least one symptom or clinical sign of dry eye by administering a therapeutically effective amount of the same type of composition comprising an adiponectin peptidomimetic compound and a pharmaceutically acceptable carrier. Symptom and clinical sign targeting is supported by lists that include redness, discharge, excessive tearing, inability to produce tears, dryness, irritation, itchiness, pain, discomfort, inflammation, fatigue, foreign body sensation, light sensitivity, and blurred vision, as well as tear and ocular surface changes such as change in tear volume, tear film stability, tear osmolarity, and corneal epithelial defects. The documented framework encompasses administration and formulation types suitable for ocular use.

For ocular diseases associated with inflammation, the invention provides methods of treating an ocular disease associated with inflammation by administering a therapeutically effective amount of a composition comprising an adiponectin peptidomimetic compound selected from the specified SEQ ID options or derivatives and a pharmaceutically acceptable carrier. The inflammatory ocular disease indication is supported by a selectable group of eye conditions, including uveitis, scleritis, post-eye surgery inflammation, corneal transplantation, corneal wound healing, conjunctivitis, retinal disease, glaucoma, ocular hypertension, and pterygium. Supporting preclinical data in scopolamine-induced dry-eye models are described, showing increased tear volume and reduced corneal staining/irregularity after topical adiponectin peptidomimetic treatment compared to control and recombinant globular adiponectin.

Claims Coverage

The independent claims identified are clm-00001, clm-00007, and clm-00010. Across these, the claims share the core composition of an adiponectin peptidomimetic compound selected from specified sequences or derivatives plus a pharmaceutically acceptable carrier, with inventive features focused on the therapeutic method and the treated target.

Across the independent claims, the main inventive focus is the use of an adiponectin peptidomimetic compound selected from the specified SEQ ID NOs or derivatives, combined with a pharmaceutically acceptable carrier, administered in a therapeutically effective amount for treating dry eye, alleviating at least one symptom or clinical sign of dry eye, or treating an ocular disease associated with inflammation.

Stated Advantages

Documented Applications